This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Nov 28;134(22):1883-1884.

doi: 10.1182/blood.2019003244.

CLL: deep dive for residual cells by NGS matters

Clemens-Martin Wendtner

PMID: 31778541
DOI: 10.1182/blood.2019003244

Free article

Comment

CLL: deep dive for residual cells by NGS matters

Clemens-Martin Wendtner. Blood. 2019.

Free article

. 2019 Nov 28;134(22):1883-1884.

doi: 10.1182/blood.2019003244.

Author

Clemens-Martin Wendtner

PMID: 31778541
DOI: 10.1182/blood.2019003244

No abstract available

PubMed Disclaimer

Comment on

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Thompson PA, et al. Blood. 2019 Nov 28;134(22):1951-1959. doi: 10.1182/blood.2019001077. Blood. 2019. PMID: 31537528 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems